Deadline: 07-Jul-2026
Pfizer is inviting proposals for research projects that improve safe and timely COVID-19 treatment through artificial intelligence (AI) and advanced clinical decision support systems.
The programme focuses on improving access to antiviral treatment, identifying eligible high-risk patients, managing drug–drug interactions, and supporting evidence-based COVID-19 care using AI-driven healthcare solutions.
Programme Focus Areas
The grant supports projects related to:
- AI-enabled clinical decision support systems
- COVID-19 antiviral treatment access
- Identification of eligible high-risk patients
- Drug–drug interaction management
- Clinical data integration
- Safe prescribing practices
- COVID-19 disease management
- Healthcare technology innovation
- Treatment optimization using Nirmatrelvir/Ritonavir
The programme aims to improve treatment outcomes for high-risk COVID-19 patients.
Programme Objectives
The initiative seeks to:
- Improve timely antiviral treatment access
- Support treatment within five days of symptom onset
- Reduce severe disease, hospitalization, and mortality
- Strengthen clinical decision-making using AI tools
- Improve management of medication-related risks
- Enhance healthcare system efficiency and patient safety
Importance of Early Treatment
The programme highlights the importance of:
- Early antiviral intervention for high-risk patients
- Rapid patient identification and eligibility screening
- Safe prescribing through drug–drug interaction management
Effective treatment timing is considered essential for improving outcomes and reducing complications.
Funding Support
Maximum funding available:
- Up to $500,000 USD per project
Project duration:
- Maximum of two years
The programme supports competitive research and implementation projects.
Geographic Scope
Eligible countries include:
Who is Eligible?
Eligible applicants include:
- Hospitals
- Academic institutions
- Professional societies
- Research organizations
Applicants must:
- Have a Principal Investigator based in an eligible country
- Be legally able to receive funding from Pfizer Inc.
- Play a key role in the proposed project
The programme does not support:
- Individual applicants
- Independent medical practice groups not affiliated with eligible institutions
Principal Investigator Requirements
The Principal Investigator must:
- Hold a medical or advanced professional degree
Eligible qualifications include:
- Medical degree
- Postdoctoral qualification
- Advanced nursing degree
- Pharmacy degree
- Physiotherapy degree
- Social work degree
The Principal Investigator must also:
- Be an employee or contractor of the requesting organization
Multi-Institutional Projects
For collaborative projects:
- All participating institutions must have defined project roles
- The lead organization must play a significant role in implementation
Expected Project Areas
Strong proposals may include:
- AI-based patient eligibility screening
- Clinical workflow integration tools
- Drug interaction management systems
- COVID-19 treatment optimization models
- Healthcare decision support platforms
- Real-world clinical implementation research
Tips for Applicants
Strong applications should:
- Demonstrate clear clinical impact
- Present scalable AI or digital health solutions
- Address treatment timing challenges
- Include robust patient safety strategies
- Demonstrate expertise in COVID-19 care and health technology
- Show measurable outcome indicators
Projects focused on high-risk patient populations and practical clinical integration may receive stronger consideration.
FAQ
What is the maximum grant amount?
Projects may receive up to $500,000 USD.
How long can projects run?
Projects may have a duration of up to two years.
Which countries are eligible?
Australia, Canada, China, Germany, Greece, Japan, Korea, and Taiwan.
Who can apply?
Hospitals, universities, research institutions, and professional organizations with eligible Principal Investigators.
What technologies are encouraged?
AI-enabled clinical decision support systems, patient identification tools, and drug interaction management solutions.
Conclusion
The Pfizer COVID-19 AI-Enabled Clinical Decision Support Grant Program supports innovative research projects that improve timely antiviral treatment and patient safety through artificial intelligence and advanced healthcare technologies. By strengthening clinical decision-making and treatment access, the programme aims to improve outcomes for high-risk COVID-19 patients across multiple countries.
For more information, visit Pfizer.